Welcome to our dedicated page for Arena Pharmaceuticals news (Ticker: ARNA), a resource for investors and traders seeking the latest updates and insights on Arena Pharmaceuticals stock.
This page provides a historical news archive for Arena Pharmaceuticals, Inc. (ARNA), a clinical-stage biopharmaceutical company that focused on developing investigational therapies for immuno-inflammatory and cardiovascular diseases. The news flow around ARNA captured key milestones in its clinical programs, corporate developments, and the definitive agreement under which Pfizer agreed to acquire Arena in an all-cash transaction.
Readers can review company-issued press releases covering progress in Arena’s gastroenterology, dermatology, and cardiology pipelines. These include updates on the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials of etrasimod in ulcerative colitis, the Phase 2/3 CULTIVATE program in Crohn’s disease, and Phase 2 studies of etrasimod in atopic dermatitis and alopecia areata. Additional news items describe Phase 2 development of cardiovascular assets temanogrel and APD418, as well as collaborations and option agreements related to other investigational compounds.
The archive also contains quarterly and annual financial result announcements, which detail Arena’s research and development spending, selling, general and administrative expenses, and net losses as it advanced its clinical-stage portfolio. Corporate governance and compensation-related releases, such as inducement grants under Nasdaq Listing Rule 5635(c)(4), provide further insight into Arena’s growth and hiring during its development phase.
Because Arena entered into an acquisition agreement with Pfizer, these news items primarily serve as historical context for ARNA rather than current standalone company updates. Investors, researchers, and students of the biopharmaceutical sector can use this record to trace how Arena communicated the evolution of its pipeline, its financial profile as a clinical-stage company, and the strategic rationale presented when Pfizer announced its plan to acquire Arena.
Arena Pharmaceuticals (Nasdaq: ARNA) has appointed Garry Neil, MD, as Chair of the Board and Nawal Ouzren as a new Board member. These changes aim to enhance the company’s leadership and positioning for anticipated growth. Dr. Neil has extensive experience in the pharmaceutical industry and previously served in senior roles at significant companies like Johnson & Johnson. Ouzren brings 20 years of expertise in clinical development and operations from her roles at Sensorion SAS and Shire International. CEO Amit D. Munshi emphasized that these appointments mark a pivotal moment in Arena's growth trajectory.
Arena Pharmaceuticals (Nasdaq: ARNA) has successfully completed enrollment for the Phase 3 ELEVATE UC 52 trial, focusing on etrasimod's efficacy in treating moderately-to-severely active ulcerative colitis. The trial, which includes 433 participants across 40 countries, aims to assess clinical remission at 12 and 52 weeks. Topline data from both ELEVATE UC 52 and UC 12 trials is expected in Q1 2022. Etrasimod is a potential treatment for various immune-mediated inflammatory diseases but is currently an investigational compound lacking regulatory approval.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to five new employees on January 15, 2021. The total includes 16,950 stock options and 3,470 RSUs, with an exercise price of $80.50 per share. The options have a seven-year term and vest over four years, while the RSUs vest over the same period with quarterly installments. This grant aligns with Nasdaq Listing Rule 5635(c)(4), aimed at enticing new talent to the company.
Arena Pharmaceuticals (Nasdaq: ARNA) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 AM ET. The presentation will be led by Amit D. Munshi, the Company's President and CEO. A live webcast will be available on Arena's investor relations page, with a recording accessible for 30 days post-event. Arena is committed to delivering vital medicines and adapting to global market changes.
Arena Pharmaceuticals (Nasdaq: ARNA) announced on December 15, 2020, that its Compensation Committee granted inducement stock options and restricted stock units (RSUs) to five new employees. The total grant includes 141,975 stock options and 2,460 RSUs, both having a grant date of December 15, 2020. The stock options have a seven-year term with an exercise price of $71.26, while both options and RSUs vest over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the presentation of topline results from the Phase 2b ADVISE trial for etrasimod, a novel oral treatment for moderate-to-severe atopic dermatitis, at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference. The findings support etrasimod's potential as an effective once-daily therapy. Etrasimod is designed for various immune-mediated diseases but remains investigational and unapproved.
Arena Pharmaceuticals (Nasdaq: ARNA) announced achieving its enrollment target of 372 participants for the Phase 3 ELEVATE UC 52 trial, assessing etrasimod for moderately-to-severely active ulcerative colitis. Although the trial reached its goal, screening will be extended by three weeks to accommodate additional participants. Topline data for both ELEVATE UC 52 and UC 12 trials is anticipated in Q1 2022. Etrasimod, an investigational oral drug, targets immune-mediated inflammatory diseases and is undergoing evaluation in over 400 global sites.
Arena Pharmaceuticals (Nasdaq: ARNA) announced a leadership transition in its R&D department, appointing Paul D. Streck, M.D., as Senior Vice President, Clinical Development, and Chief Medical Officer, effective December 1, 2020. This change follows the retirement of Chris Cabell, M.D., who served as the Executive Vice President and Chief Medical Officer since June 2020. Dr. Streck brings over 25 years of experience in drug development and has held leadership roles that led to several successful product launches.
Arena Pharmaceuticals (Nasdaq: ARNA) announced that CEO Amit D. Munshi will participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 1, 2020, at 4:20 PM ET. A live webcast will be accessible on Arena's investor relations page at www.arenapharm.com, with a replay available for 30 days after the event. Arena focuses on delivering essential medicines to patients, emphasizing urgency and innovative approaches in a dynamic market.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced on November 15, 2020, that its Compensation Committee has granted stock options and restricted stock units (RSUs) to 13 new employees. A total of 96,025 stock options and 17,590 RSUs were awarded as incentives for joining the company. The stock options have an exercise price of $66.68 and a seven-year term, vesting over four years. RSUs will also vest over four years. These grants comply with Nasdaq Listing Rule 5635(c)(4), which allows inducement grants to new employees.